Zoetis Inc. announced on October 16, 2025 that Health Canada has approved Lenivia (izenivetmab injection) for the alleviation of pain associated with osteoarthritis in dogs. The approval marks the first time a monoclonal antibody has received regulatory clearance to provide three‑month pain relief with a single subcutaneous injection in the canine market.
Lenivia is a novel antibody that binds to nerve growth factor (NGF) at a distinct site from existing therapies. A nine‑month field study demonstrated that dogs receiving Lenivia experienced increased mobility and decreased pain after one injection, with a safety profile consistent with prior studies of similar biologics. The product is administered once every three months, offering a convenient dosing schedule for pet owners and veterinarians.
The approval expands Zoetis’s osteoarthritis pain portfolio, adding a long‑acting therapy that complements its existing Librela product. By providing a new, extended‑duration option, Zoetis strengthens its competitive position in the companion‑animal pain market and opens a new revenue stream that could accelerate growth in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.